EARSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (26 7月 2021 @ 13:00):

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders...

Stats
本日の出来高	174 066
平均出来高	1.89M
時価総額	4.21M
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-2.05
ATR14	CHF0.243 (7.98%)

ボリューム相関

長: 0.48 (neutral)

短: 0.85 (strong)

Signal:(42.109) Same movement expected

Auris Medical Holding Ltd 相関

10 最も正の相関
EDAP	0.86
EDRY	0.853
PAYS	0.852
SQQQ	0.843
BLTE	0.84
HIBB	0.836
GOGL	0.835
CHCI	0.832
WVVI	0.83
SHIP	0.827

10 最も負の相関
INZY	-0.869
OSW	-0.863
VOXX	-0.859
TXRH	-0.857
CPRT	-0.855
EYEN	-0.853
QYLG	-0.851
LRGE	-0.85
IRTC	-0.85
QQQ	-0.85

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Auris Medical Holding Ltd 相関 - 通貨/商品

0.29
( neutral )

-0.16
( neutral )

0.00
( neutral )

0.11
( neutral )

-0.59
( weak negative )

-0.26
( neutral )

Auris Medical Holding Ltd 財務諸表

Annual	2023
収益:	CHF0
総利益:	CHF0 (0.00 %)
EPS:	CHF-14.80

FY	2023
収益:	CHF0
総利益:	CHF0 (0.00 %)
EPS:	CHF-14.80

FY	2022
収益:	CHF305 616
総利益:	CHF-1.14M (-372.44 %)
EPS:	CHF-29.13

Financial Reports:

No articles found.

Auris Medical Holding Ltd

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.